The finding that CXCR5+Th17 cell frequency at baseline correlates with swollen joints at baseline and at one year post-TNFi therapy could indicate that patients with high CXCR5+Th17 frequencies have more severe joint disease, which is therefore more refractory to therapy. The gene discussed is CXCR5; the disease is arthropathy.